By Chelsey Dulaney
Priceline Group Inc. gave a disappointing outlook for its current quarter as bookings are expected to slow and foreign currency effects weigh on its performance, despite posting a better-than-expected 19.4% surge in revenue in its December-ended quarter.
Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™,
announced today that preclinical data for CRLX101 as monotherapy and in
combination with Avastin ® have been selected to be the
subject of an oral presentation at the 17th Annual Symposium on
Anti-Angiogenesis and Immune Therapies for Cancer to be held February
19-21, 2015 in San Diego, California.
By Chelsey Dulaney
T-Mobile US Inc. swung to a profit in its holiday quarter on a better-than-expected 19.4% surge in revenue, though the company warned that profitability will be hit in its current quarter by a large investment in customer growth.
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical
company focused on the discovery, development and commercialization of
novel protein therapeutics for cancer and rare diseases, today announced
that new preliminary data from the DART study, an ongoing phase 2
clinical trial of dalantercept in patients with advanced renal cell
carcinoma (RCC) will be presented at the American Society of Clinical
Oncology (ASCO) 2015 Genitourinary Cancers Symposium in Orlando,
Global, Inc. (NASDAQGS:JCOM), the global provider of Internet
services, today announced that its Campaigner ®
Email Marketing brand has acquired the assets of EmailDirect, a
California-based provider of email marketing services.
By Sara Sjolin, MarketWatch
SolarCity slides premarket after earnings
LONDON (MarketWatch) -- U.S. stocks were poised for a weak open on Wall Street on Thursday, with futures hit by a sharp fall in oil prices and investors staying on the sidelines ahead of a raft of earnings reports and economic data.
BUDAPEST--Pharmaceutical firm Richter Gedeon Nyrt., Hungary's largest home-grown drug maker signed a deal with US-based peer Evestra Inc on providing it with a $5 million convertible loan for drug development.
By Alistair MacDonald
Barrick Gold Corp, the world's biggest gold miner by production, announced a fourth quarter net loss of $2.85 billion as the Canadian company added billions of dollars in impairments to the long list of write downs it has already made.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.